This paper proposes dynamic treatment regimes (DRTs) for choosing individualized effective treatment strategies of chronic periodontitis. The proposed DTRs are studied via SMARTp -a two-stage sequential multiple assignment randomized trial (SMART) design. For this design, we propose a statistical analysis plan and a novel cluster-level sample size calculation method that factors in typical features of periodontal responses, such as non-Gaussianity, spatial clustering, and non-random missingness. Here, each patient/subject is viewed as a cluster, and a tooth within a subject's mouth is viewed as an individual unit inside the cluster, with the tooth-level covariance structure described by a conditionally autoregressive process. To accommodate possible skewness and tail behavior, the tooth-level clinical attachment level (CAL) response is assumed to be skew-t, with the non-randomly missing structure captured via a shared parameter model corresponding to the missingness indicator. The proposed method considers mean comparison for the regimes with or without sharing an initial treatment, where the expected values and corresponding variances or covariance for the sample means of a pair of DTRs are derived by the inverse probability weighting and method of moments. Simulation studies are conducted to investigate the finite-sample performance of the proposed sample size formula under a variety of outcome-generating scenarios. A major contribution of this work is the implementation of the sample size formula via a R package available in GitHub.
Introduction
sponses are available at the cluster sub-unit level (teeth) level. Although sample size formulas and SMART design implementations under clustered outcomes setting are available (Ghosh et al., 2016; NeCamp et al., 2017) , they only focus on regimes that do not share an initial treatment. Furthermore, they do not account for other data complications typical to PD studies, such as presence of (i) non-Gaussian (skewed and thick-tailed), (ii) non-randomly missing, and (iii) spatially-referenced CAL responses (Reich et al., 2013) . For example, consider the motivating GAAD data, which recorded the extent of PD in a Type-2 diabetic Gullah-speaking African American population from the coastal South Carolina sea-islands (Fernandes et al., 2009) . For illustration, panel (a) in Figure 1 describe the measurement locations and sample data for a random subject, while panel (b) plots the density histogram of the CAL for the four tooth-types from the GAAD dataset, revealing considerable right-skewness. Furthermore, PD being the major cause of adult tooth-loss, it is likely that patients with higher level of CAL (and CP) exhibit a higher proportion of missing teeth, and hence this missingness mechanism is non-ignorable (Reich et al., 2013) .
Also, CP and PD are hypothesized to be spatially-referenced, i.e., proximally located teeth usually have similar disease status than distally located ones. Ignoring the features (i)-(iii) in constructing any SMART design for CP may lead to imprecise estimates of the desired parameters. It is important to note here that the Ghosh et al. (2016) approach of a clustered SMART design considers traditional clustering (sub-units within a cluster) of Gaussianly distributed continuous responses, and excludes spatial clustering and other features.
In this paper, we set forward to address the aforementioned limitations in developing a list of plausible DTRs for treating CP. We cast this into a two-stage SMART design framework for CP outcomes that exhibit (i)-(iii), and present an analysis plan and sample size calculations for (a) detecting a postulated effect size of a single treatment regime, and (b) detecting a postulated difference between two treatment regimes with or without a shared initial treatment. The tooth-level covariance structure describing spatial-association is modeled by a conditionally autoregressive process (Reich and Bandyopadhyay, 2010) . To accommodate possible skewness and tail behavior, the tooth-level CAL responses are assumed to have skew-t (Azzalini and Capitanio, 2003a) errors, with the nonrandomly missing CAL values imputed via a shared parameter model corresponding to the missingness indicator.
The proposed method considers mean comparison for the regimes with or without sharing an initial treatment, where the expected values and corresponding variances or covariance of the effect size of the treatment regimes are derived by the inverse probability weighting (IPW) techniques (Robins et al., 1994b) , and method of moments.
The rest of the paper is organized as follows. Section 2 introduces eight potential treatment, and the corresponding DTRs that constitute the 2-stage SMART design for CP. Section 3 presents the theoretical framework and a sample size calculation method under this SMART design, incorporating the aforementioned features typical to PD data. Section 4 investigates the finite-sample performance of the proposed sample size calculation method using synthetic data generated under various settings. Section 5 demonstrates the implementation of the R function SampleSize.SMARTp for calculating sample sizes, also available at the GitHub link Figure 1: CAL data. Panel (a) shows the observed CAL for a patient with a missing incisor, where the shaded boxes represent teeth, the circles represent sites, and gray lines represent neighbour pairs that connects adjacent sites on the same tooth and sites that share a gap between teeth. "Gap" in the figure indicates, for example, the four sites in the gap between teeth # 4 and 5. The tooth numbers are indicated, and excludes the 4 third-molars: 1, 16, 17 32. The vertical and horizontal lines separate the mouth into four quadrants, with the molars (# 2-3, 14-15, 18-19, 30-31) , premolars (# 4-5, 12-13, 20-21, 28-29) , canines (# 6, 12, 22, 27) and incisors (# 7-10, 23-26) . Panel (b) presents the frequency density plot of the CAL (rounded to the nearest mm) for each tooth type from the GAAD dataset.
https://github.com/bandyopd/SMARTp. Finally, the paper ends with a discussion in Section 6. Supplementary Material, consisting of detailed derivations are relegated to the Appendix.
A SMART design for the DTRs
In this section, we propose dynamic treatment regimes (DTRs) for treating CP, which are studied via a SMART design. A list of possible treatments consist of the treatment initiation steps: (1) Oral hygiene instruction, and (2) Education on risk reduction. This is followed by (3) SRP, or more advanced non-surgical treatments that combine SRP with adjunctive therapy, as summarized in the systematic review of Smiley et al. (2015) , such as (4) SRP with local antimicrobial therapy, (5) SRP with systemic antimicrobial therapy, (6) SRP with photodynamic therapy, which uses lasers, but only to activate an antimicrobial agent), (7) SRP with systemic subantimicrobial-dose doxycycline (SDD), and finally, (8) Laser. The corresponding SMART design for developing DTRs is presented in hygiene instruction, 2=education on risk reduction, 3=scaling and root planing (SRP), 4=SRP with local antimicrobial therapy, 5=SRP with systemic antimicrobial therapy, 6=SRP with photodynamic therapy, 7=SRP with systemic sub-antimicrobial-dose doxycycline (SDD), 8=laser therapy.
Oral hygiene is primarily used for prevention and initial therapy, especially during early stage of periodontitis.
At the beginning of the proposed trial, each participant has to attend the treatment initiation steps (1) and (2) before any randomization. Note that while SRP is the accepted gold-standard, the role of laser therapy, though advantageous in targeting the diseased area precisely and accurately, still remains controversial as a standard of care. In this paper, we develop our SMART design, with a primary focus on comparing the DTRs starting with either SRP (# 3), or Laser therapy (# 8). At the initial stage, each participant is randomly allocated to either treatment 3 or 8.
We propose a DTR that matches an patient's's need in achieving similar outcome as SRP with adjuncts, though at a lower cost. Each possible treatment regime can have more than one path of treatment according to each patient's evolving response. The patients who respond to the initial treatment continue the same treatment at the 2nd stage of the trial. The patients who do not respond to treatment 3 are randomly allocated to one of the treatments 4-7 in the 2nd stage. Similarly, for patients allocated to the laser arm (treatment 8), the non-responders will also have the provision of being randomly allocated to one of 4-7 in the 2nd stage. The randomization probabilities calculated at both the initial and final stages of our SMART design is presented in Section 3.3. The primary final outcome measure is the recorded and rounded tooth-level CAL. The possible paths are listed below, i.e.
• Path 1: '1', '2', '3', '3'
• Path 2: '1', '2', '3', '4'
• Path 3: '1', '2', '3', '5'
• Path 4: '1', '2', '3', '6'
• Path 5: '1', '2', '3', '7'
• Path 6: '1', '2', '8', '8'
• Path 7: '1', '2', '8', '4'
• Path 8: '1', '2', '8', '5'
• Path 9: '1', '2', '8', '6'
• Path 10: '1', '2', '8', '7' This leads to eight different DTRs (d 1 -d 8 ) that are embedded within the two-stage SMART design, i.e.
Here, Regime 1 can be explained as following treatments 1 and 2, a patient undergoes treatment 3 (considered as treatment at initial stage). If that patient responds (R) to the initial treatment, he or she continues with treatment 3 at 2nd stage, while a non-responder (NR) will receive treatment 4 at the 2nd stage. The other regimes can be explained similarly. There are a number of advantages (Chakraborty and Moodie, 2013) In this section, we propose the theoretical framework and a novel sample size formula for our SMART design.
Statistical Model
We start with introducing some notations. Let A i1 denote the treatment for patient i at the initial stage (i.e. '3' or '8'); R i (A i1 ) denote the proximal response after initial treatment A i1 , i.e R i (·) = 1 if the i th patient is a responder and R i (·) = 0 otherwise; A i2 (A i1 , R i (A i1 )) denote the treatment at final stage based on initial (first) stage treatment and response; Y it denote the final outcome measure, i.e. change in mean CAL for the t th teeth of patient i;
M it denotes the missingness indicator of the t th teeth of patient i, i.e. M it = 1 if missing, or 0 otherwise. Thus, the observed data trajectory for patient i can be described as
). Note that we have N patient in the sample, and each patient has a maximum of 28 teeth (if no tooth is missing). Thus, the (overall) outcome measure for patient
, which is the mean of CAL of the available teeth for patient i. Hence the proportion of the available teeth for patient
The regression model for Y is given by:
for i = 1, . . . , N and t = 1, . . . , 28, where
Here, A i13 is an indicator of treatment '3' at initial stage for patient i, A i24 is an indicator of treatment '4' at final stage for patient i, and it1 is the (random) error term distributed as a skew-normal (SN(, or skew-t (ST) density (Azzalini and Capitanio, 2003b) , i.e., it1 ∼ ST (0, σ 2 1 , λ, ν), with location parameter 0, scale parameter σ 1 , skewness parameter λ, and degrees of freedom ν that measure the kurtosis. Note, the distribution of it1 is normal if λ = 0 and ν = ∞, skew-normal if λ = 0 and ν = ∞, t if λ = 0 and ν < ∞, and skew-t, if λ = 0 and ν < ∞. Expressions of the mean, variance, skewness γ 1 and kurtosis γ 2 for both SN and ST distributions are presented in Appendices A and B respectively. Following Reich et al. (2013) , we assume the latent vector Q i =(Q i1 , . . . , Q i28 ) follows a multivariate normal distribution, with mean vector 0 28×1 and covariance matrix Σ 28×28 with a conditional autoregressive (CAR) structure, i.e. Σ 28×28 = τ 2 (C 28×28 − ρD 28×28 ) −1 . Here, τ 2 > 0 and ρ ∈ [0, 1] are the parameters controlling the magnitude of variation, and degree of spatial association, respectively. For matrix D, the elements D tt are ones if locations t and t are adjacent, and zeroes otherwise. The matrix C is diagonal with diagonal elements C tt = t D tt .
Next, under the assumption of non-randomly missing teeth (locations of missing teeth are not random, but rather related to the CP health in that region of the mouth), we propose a probit regression model for the missing teeth indicator as a function of the underlying (spatial) latent term Q i . Define M it = I(M it0 > 0), where M it0 is a (latent) continuous variable, modeled as:
where it0
For sake of identifiability, we choose σ 2 0 = 1. Here, under the popular sharedparameter framework (Vonesh et al., 2006) , Q facilitates sharing of information between Y and M for modeling non-randomly missing data. The parameters a 0 , b 0 , and the estimates Q i and it0 determine the proportion of available tooth p i = E(p i ), which can be estimated using either stochastic or deterministic method (see Appendix C). The parameter b 0 controls the association between Y and M , e.g., b 0 = 0 indicates no association. For example, the Pearson correlation coefficient between Y it and M it0 (from (2)
, see Appendix C for the derivation. For power analysis, one may choose the distributions of Q i , it1 and it0 from the literature, e.g., Reich and Bandyopadhyay (2010) . Define c i = t c it /28. The clinician may suggest values for µ i , p i and c i , and the corresponding estimates of a 0 and b 0 can be obtained by solving aa set of simultaneous equations involving p i and c i .
Next, we derive the expected value and variance for the sample mean of a DTR, using d 1 as an example, based on the IPW principle. IPW techniques have been successfully applied for estimating regression coefficients (Robins et al., 1994a) , and population mean (Cao et al., 2009) , in the context of incomplete data. For DTRs under SMART designs, most likely, we are unable to sample data directly from a particular regime. For example, responders of SRP can be classified as either regimes 1-4. Hence, a method of moments estimate of the sample mean for regime 1 is given by:Ȳ
where To maximize power, we estimate π d 1 1i as in (Murphy, 2005) to have equal sample sizes across all possible regimes. We set
where γ d 1 denotes the response rate for regime 1 at initial stage. If γ d 1 and γ d 5 are not known, we set
Alternatively, we set π
, if equal probability of treatment allocation at initial stage is required.
The mean and variance ofȲ d 1 are derived below. We have
In terms of π, γ, µ and σ, (7) and (8) can be expressed alternatively as
Hypothesis 1 can be used to test whether the improvement in CAL in the proposed DTR is better than SRP (e.g., ≥ 0.5mm), or not worse than SRP with adjuncts (e.g., 0.7-1.1 mm), based on the systematic review results of Smiley et al. Smiley et al. (2015) . Since the network meta-analyses by John et al. John et al. (2017) found no significant evidence of CAL improvement among adjuncts, Hypothesis 2 can be used to test if indeed there are statistically significant differences between the DTRs of SRP and 'SRP + adjuncts'. The treatment effect of laser therapy is still under investigation; we can use Hypothesis 3 to test if there is a statistically significant difference between the DTRs initialized by SRP and laser.
Consider Hypothesis 2. The Expectation and variance of regimes difference can be expressed respectively as
and
Note, both δ and σ 2 in equations (9) and (10) respectively are functions of the parameter vector
). Note, µ, τ , ρ, λ, ν, σ 2 1 , σ 2 0 , a 0 and b 0 are defined in equations (1) and (2), while parameters γ's and π's are defined in equations (3) to (5). The covariance
, since the responders from treatment '3' are consistent with both the treatment regimes 1 and 3. The derivations of both E( 
Assumptions: 
3. The possible sets for regime means and effect size
is continuous at each δ, with probability one;
Though the regimes 1 and 5 do not share any initial treatments, the covariance between the sample mean of these two regimes can be derived in the similar way as COV
Before deriving the sample size formula, we present the test statistics for the corresponding hypotheses below.
is given in (10). In large samples, Z follows a standard normal distribution if H 0 is true. Hence, at α level of significance, we reject H 0 if | Z |> z α/2 , where z α/2 is the upper α/2 quantile of a standard normal distribution. In a similar way, the test statistic for Hypothesis 1 (H 0 :
/N respectively, where both follow standard normal distribution if H 0 is true.
Sample size calculation
The calculated sample size is possible to detect the effect size of either a single regime or the difference between two regimes. The proposed sample size formulas for Hypothesis tests 1-3 under our SMART design are given by
respectively, where σ 2
is defined by (10), and in the similar way, both σ 2
can also be defined; α =Pr(Type one error), β =Pr(Type two error)= 1 -Power, Pr(z > z α/2 ) = α/2 and Pr(z > z 1−β ) = 1−β, the ef-
Therefore, we define the standardized effect size by δ *
our calculations advance the previous ones for SMART designs in clustered data (Ghosh et al., 2016; NeCamp et al., 2017) by including non-Gaussianity, spatial association, and non-random missingness features, typical for periodontal responses, in addition to considering comparisons between regimes that shares the same initial treatment. Also, the patients (or clusters) are randomly allocated with equal probability for each regime, which requires smaller sample size than allocation with equal treatment probability at each stage.
Simulation studies
We now present simulation studies to investigate the finite-sample performance of the proposed sample size formulas (11) to (13) in terms of computing Monte Carlo power estimates based on 5000 simulated data sets, given the type-II error rate β = 0.2, or nominal power of 80% and type-I error rate α = 0.05. We also compare the theoretical and Monte Carlo mean and variance of the estimated effect sizes for the DTRs.
The Monte Carlo data generation steps are given below. These include generating the random variables A i1 ,
Step 1 The initial treatment A i1 is assigned randomly to either '3' or '8', with probability π
Step 2 The response variable
where γ d 1 = 0.25 or 0.5 and γ d 5 = 0.5.
Step 3 The final treatment A i2 (A i1 = '3', R i (A i1 = '3') = 1) is assigned to '3' with probability of 1, and
is randomly assigned to'4', '5', '6' or '7' with probability of 1/4, while
is assigned to '8' with probability 1 and A i2 (A i1 = '8', R i (A i1 = '8') = 0) is assigned to '4', '5', '6' or '7' with probability of 1/4.
Step 4 The change in mean CAL Y it and missingness indicator M it of each tooth are generated by regression models (1) and (2), at λ = 10 and ν = 6, the association between CAL change and missingness is around 0.44 (i.e. c i ≈ 0.44).
Step 5 The mean CAL change for patient i is computed
. Tables 1 -3 |) and treatments '3' response rate(γ d 1 ), skewness parameter (λ) and degree of freedom (ν), given treatment '8' response rate γ d 5 = 0.5, σ 1 = 0.95, σ 0 = 1, ρ = 0.975, τ = 0.85, expected % available teeth per patient p i = 80%. |) and treatments '3' response rate(γ d 1 ), skewness parameter (λ) and degree of freedom (ν), given treatment '8' response rate γ d 5 = 0.5, σ 1 = 0.95, σ 0 = 1, ρ = 0.975, τ = 0.85, expected % available teeth per patient p i = 80%. Figure 2 defines the SMART design. The first three inputs of the function SampleSize.SMARTp(mu, st1, dtr, regime, pow, b, a, rho, tau, sigma1, lambda, nu, sigma0, Num, p i, c i, a0, b0, cutoff) are matrices, defined as:
• mu: mean matrix, where rows represent treatment paths and columns represents cluster sub-units (i.e. teeth) within a cluster (mouth),
• st1: stage-1 treatment matrix, where rows represent the corresponding stage-1 treatments, the 1st column includes the numbers of treatment options for responder, the 2nd column includes the numbers of treatment options for non-responders, the 3rd column are the response rates, and the 4th column includes the row numbers of matrix 'st1',
• dtr: matrix of dimension (# of DTRs X 4), the 1st column represents the DTR numbers, the 2nd column represents the corresponding treatment path numbers of responders for the corresponding DTRs in the 1st column, the third column represents the corresponding treatment path numbers of the non-responders for the corresponding DTRs in the 1st column, while the 4th column represents the corresponding initial treatment.
The regime can be, a vector of two regime numbers if the hypothesis test is to compare regimes, or a single regime number if the hypothesis test is to detect the effect of that regime. The power, type-2 and type-1 error rates, given by pow, b and a respectively, with the corresponding defaults 0.8, 0.2 and 0.05. The parameters τ and ρ, which quantifies the variation and association in the CAR specification of the random effect Q it are given by tau and rho, respectively, with defaults set at tau = 0.85 and rho = 0.975. The inputs sigma1, lambda and nu define the scale (σ 1 ), skewness (λ) and degrees of freedom (ν) parameters of the residual it1 , which defaults to sigma1 = 0.95, lambda = 0 and nu = Inf. The standard deviation σ 0 for the residual it0 is given by sigma0, whose default is sigma0 = 1. The rest of the parameters a 0 , b 0 and c 0 from (2) are specified by a0, b0 and cutoff respectively, and their defaults are a0 = -1, b0 = 0.5 and cutoff = 0. The user can either provide the choice of a0 and b0, or the choice p i and c i, which are the expected proportion p i of available teeth for patient i, and the average Pearson's correlation coefficient c i between Y it and M it0 , averaged over the 28 teeth for patient i, respectively.
Monte Carlo estimates of the mean and variance ofȲ i for each treatment path were obtained using Num random samples.
The possible outputs are summarized below:
• N, the calculated sample size,
• Sigma, the CAR covariance matrix of Q it , i.e. Σ 28×28 ,
• ybard1, the regime mean corresponding to the 1st element of regime, which is µ d 1 if, for example,
• ybard2, the regime mean corresponding to the 2nd element of regime, which is µ d 5 if, for example, regime = c(1, 5); 0, if regime = c(1),
• sig.d1.sq, N×the variance of the estimated regime mean corresponding to the 1st element of regime,
• sig.d2.sq, N×the variance of the estimated regime mean corresponding to the 2nd element of regime,
• sig.d1d2, N×the covariance between the estimated regime means correspond to regime, which is
• sig.e.sq, N×the variance of the difference between the estimated regime means correspond to regime,
• Del, absolute value of the effect size, which is
• Del std, absolute value of the standardized effect size,
for example, regime = c(1,5),
• p st1, randomization probability of stage-1 for each treatment path,
• p st2, randomization probability of stage-2 for each treatment path,
• res, a vector with binary indicators denoting responders and non-responders that corresponds to a treatment path,
• ga, response rates of initial treatments corresponding to each treatment path,
• initr, a vector with dimension as the number of treatment paths, whose elements are the corresponding row number of st1.
In the following, we present the R codes for the sample size calculation corresponding to the second row of Table   3 in Section 4. 
## I t e r a t i o n s i z e

Num = 1000000
Then, the R codes to compute N ,
are respectively: 
Discussion
This paper proposes a two-stage SMART design to study a number of DTRs for managing CP. A statistical analysis plan under this design includes hypothesis testing of detecting an effect size for either a single regime, or the difference between two regimes with or without sharing an initial treatment. This paper also develops a novel sample size calculation method, accommodating typical statistical challenges observed in CP data, such as nonGaussianity, spatial association, and non-random misingness. To the best of our knowledge, this is the first SMART proposal in CP research within the umbrella of precision oral health -a major goal in the NIH/NIDCR's Strategic
Plan 2014-2019, and advances previous SMART proposals (Ghosh et al., 2016; NeCamp et al., 2017) considered for clustered data.
An appealing feature of our method is the availability of R codes for implementation. However, with precision oral health as a recently emerging field, there are no real data to support the input information in the proposed sample size formula. We recommend considering plausible assumptions, such as medium effect size, conservative sample sizes, etc, to come up with the input values for implementing our proposed SMART design. Additionally, they can be referenced by estimates from existing single-stage clinical trials. However, our experimental design, statistical analysis plan or sample size calculation can be updated or improved through data collection.
Similar to Oetting et al. (2011) , the proposed sample size method can also be extended to determine the optimal treatment regime. Our method can be easily updated to include more therapies (such as, various kinds of laser), and the number of treatment stages (which leads to close monitoring of CAL changes), with each stage considering more treatment types. Also, by using the Q-function approach that minimizes squared error (NeCamp et al., 2017) , or maximizing likelihood (Van Der Laan and Rubin, 2006) , the effect size of DTRs can be adjusted by adding baseline characteristics, such as age, gender, education, oral hygiene, etc, into the regression models (1) or (2).
These are important avenues for future research, and will be considered elsewhere.
The density function of W is
where
denotes the density function of a m-dimensional t variate with location ξ, shape matrix Ω and degrees of freedom ν, while T 1 (·; ν + m) denotes the cdf of an univariate student's t with degrees of freedom ν + m. We can use the expression Y = ξ + ωX to compute the moments of Y, i.e. the n-th moment of Y is
with E(X n ) given in Azzalini and Capitanio (1999) . Thus, the mean and variance, are, respectively,
Similarly, the skewness (γ 1 ) and kurtosis (γ 2 ) for the univariate cases are
.
C Sample size formula derivation
The covariance between Y it and M it0 is
where Σ tt is the t th diagonal elements of the covariance matrix Σ 28×28 . The Pearson correlation coefficient is
1+λ 2 . Now, we derive an expression for p i , i.e.,
where Φ(·) is the cdf of z ∼N(0,1). Now,
In a similar way, we have E(
According to variance decomposition, the right side of (8) is the sum of two components, which are
The first component is
while the second component is
with µ d 1 R , the expectation ofȲ i from d 1 , with R i = 1, given by
where f (Q i ) and f ( i ) are the density functions for Q i and i respectively. Also, σ 2 d 1 R , the variance ofȲ i that is from d 1 , with R i = 1, can be written as
Similarly, we have
, where µ 2 d 1 N R and σ 2 d 1 N R are the expectation and variance ofȲ i from d 1 with R i = 0. Therefore, the second component is
Thus, the variance formula (8) is
The variance of the difference between d 1 and d 3 is
The covariance betweenȲ
Therefore, the variance of regime means differences between d 1 and d 3 is
D Proof of Theorem 1
Proof:
The proof ofconsistency requires the result of strong law of large numbers, such that ).
